Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-846 pharmacokinetics in healthy males
NCT06110923Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Nov 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-846 in benign prostatic hyperplasia (BPH) (5 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration of CKD-846 at 24 hours and Maximum Plasma Concentration of D091 at 96 hours. Started Nov 2023; status: completed.
02
Drugs
CKD-846
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT06110923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06110923.